1 1 Mosapride sustained-release formulation for providing pharmaceutical clinical effects with once-a-day dosing

摘要

The oral preparation containing the simulated fibrin of the present invention or a salt thereof may be used as a continuous layer for rapidly releasing the drug and a slow release layer for gradually releasing the drug in order to simultaneously satisfy the rapid pharmacological activity and the sustained pharmacological activity for 24 hours (HPMC) and low-viscosity hydroxypropyl methylcellulose (HPMC) were mixed and used in such a manner that the ratio of high-viscosity hydroxypropyl methylcellulose (HPMC) Thereby controlling the dissolution rate and / or the residence time in the gastrointestinal tract in each part of the gastrointestinal tract having different pH. In addition, the present invention has the advantage of improving the patient compliance with the medicament because the total weight is 200 mg or less, preferably 150 to 160 mg.